Pfizer reports 1st quarterly loss since 2019 on weak COVID product demand – National
Pfizer on Tuesday urged investors to focus on growth in its non-COVID products such as its new RSV vaccine Abrysvo, after weak demand for its COVID-19 vaccine and treatment pushed the drugmaker to its first quarterly loss since 2019.…
Read More...
Read More...